According to the SEC's complaint, Harold Altvater, whose wife was an Ariad employee, allegedly made multiple illegal trades in Ariad stock on the basis of non-public information he learned from her. Maureen Curran, a former Ariad executive, sold Ariad stock in December 2012, after she had attended meetings with the FDA and had learned material nonpublic information regarding a forthcoming FDA decision. Susan Dubuc, another former executive, allegedly tipped relatives in October 2013, one day before Ariad publicly announced a pause in all clinical trials for its FDA-approved drug. Without admitting or denying the SEC's allegations, Curran and Dubuc have settled with the SEC subject to court approval. Curran agreed to pay $20,248 in disgorgement, penalties and interest. Dubuc agreed to pay $6087. The charges against Altvater are still pending.